1.The Study of The Applied Anatomy of The Jugular Fossa
Journal of Kunming Medical University 1988;0(03):-
The anatomical relations of the jugular fossa with the vertical portion of the facial canal, the posterior cranial fossa and the tympanic ring were surveyed in 100 adults, skulls(57 males, 43 females); the dimensions of the jugular fossa were measured. The depth of the jugular fossais 7.73?0.33(2.0-1.52mm) at left, 9.47 ? 0.34mm(2.8-19.0mm) at right. The thickness of the bony plate separating the jugular fossa from the vertical partion of the facial canal is 2.77 ?0.17(1.5-2.8mm) at left, 2.33?0.17mm(1.0-2.9mm) at right. The top of the jugular fossa above the tympnic ring level is accounted for 35% at left, 62.24% at right. In these surveys, some anatomical variances were observed. These data can give the reference to the clinicians in the operations of the facial nerve and the jugular bulb.
2.Observation and Measurement of Chinese Tympanic Membrane,Meatus Acusticus Externus and Porus Acusticu Externus
Journal of Kunming Medical University 1988;0(03):-
85 adult(42 right,43 left),30 newborn(18 right,12 left)and 32 fetal(13 right,19 left)samples were investigated.The vertical and transverse diameters of the tympanic mendrane were measured.The results might be for reference in isop- lastic transplantation.
3.Stimulation of TLR3 inhibits the proliferation of breast cancer cells MDA-MB-231
Shuxia XU ; Dandan CHEN ; Fengxia MA ; Yueru JI ; Lijuan RONG ; Fang CHEN ; Ying CHI ; Shaoguang YANG ; Shihong LU ; Zhongchao HAN
International Journal of Biomedical Engineering 2012;35(2):74-78
ObjectiveToll-like receptors (TLRs) play important role in the progression and tumor immunity of some types of cancer,some research have demonstrated that agonist of TLR3 can trigger apoptosis of cancers.This study was proposed to investigate if Poly(I:C),the specific agonist of TLR3,could impact proliferation or apoptosis of progressive breast cancer cells MDA-MB-231,and to investigate the primary mechanism of the function.MethodsExpression of TLR1-10 mRNA was detected by quantitative real-time reverse transcription-polymerase chain reaction.Cell Counting Kit-8 was used to determine the inhibitory effect of Poly(I:C) on proliferation of MDA-MB-231 cells.Cell apoptosis was assayed by flow cytometry with V-FITC/PI staining.Results First,the toll-like receptors 1-10 were all expressed on MDA-MB-231 cells,while the expression level of TLR8 was lower than that of others.Second,according to the CCK-8,the proliferation of MDA-MB-231 cells was inhibited,but the apoptosis was not affected on the basis of Apoptosis Kit.At last,the mRNA expression of TNF-α、IFN-β and IFN-γ were elevated approximately 20 times after Poly(I:C) stimulation for 6 hours.ConclusionMDA-MB-231 cells express all toll-like receptors on mRNA level,and TLR8 was expressed lower than others.The stimulation of TLR3 with Poly(I:C) can inhibit the proliferation of MDA-MB-231,but had no effect on apoptosis.TNF-α、IFN-β and IFN-γ maybe participate in this process.
4.Epidemiological research progress on the impact of pollutants emitted from coal-fired power generation on the cardiopulmonary health of the population
Shuhui WAN ; Yueru YANG ; Jiahao SONG ; Bin WANG ; Weihong CHEN
Chinese Journal of Preventive Medicine 2024;58(3):381-388
To achieve the goals of carbon peak and carbon neutrality (double carbon), China has been updating and developing low-carbon coal-fired power generation technology. While reducing carbon dioxide emissions, it has achieved a significant reduction in emissions of pollutants such as particulate matter, sulfur dioxide, and nitrogen oxides. However, at the same time, with the relative increase in emissions of certain pollutants such as sulfur trioxide, ammonia, and volatile organic compounds, the types and proportions of pollutant emissions have changed. This study summarized the technological improvements in coal-fired power generation both domestically and internationally, as well as the types and proportions of pollutants emitted by different coal-fired power generation modes. It also reviewed the epidemiological research progress on the impact of pollutants emitted from coal-fired power generation on the cardiopulmonary health of the population, expounded environmental impact of different coal-fired power models, and analyzed the changes in population exposure load and cardiopulmonary health benefits of low-carbon coal-fired power generation emissions, aiming to provide references for achieving carbon reduction and emission reduction goals and protecting the health of the population.
5.Epidemiological research progress on the impact of pollutants emitted from coal-fired power generation on the cardiopulmonary health of the population
Shuhui WAN ; Yueru YANG ; Jiahao SONG ; Bin WANG ; Weihong CHEN
Chinese Journal of Preventive Medicine 2024;58(3):381-388
To achieve the goals of carbon peak and carbon neutrality (double carbon), China has been updating and developing low-carbon coal-fired power generation technology. While reducing carbon dioxide emissions, it has achieved a significant reduction in emissions of pollutants such as particulate matter, sulfur dioxide, and nitrogen oxides. However, at the same time, with the relative increase in emissions of certain pollutants such as sulfur trioxide, ammonia, and volatile organic compounds, the types and proportions of pollutant emissions have changed. This study summarized the technological improvements in coal-fired power generation both domestically and internationally, as well as the types and proportions of pollutants emitted by different coal-fired power generation modes. It also reviewed the epidemiological research progress on the impact of pollutants emitted from coal-fired power generation on the cardiopulmonary health of the population, expounded environmental impact of different coal-fired power models, and analyzed the changes in population exposure load and cardiopulmonary health benefits of low-carbon coal-fired power generation emissions, aiming to provide references for achieving carbon reduction and emission reduction goals and protecting the health of the population.
6.Cost-utility analysis of semaglutide versus canagliflozin in patients with type 2 diabetes poorly controlled with metformin
Yueru XU ; Yubo WANG ; Huimin PAN ; Huiting SHAN ; Ji CHEN ; Jianhua YANG
China Pharmacy 2025;36(9):1087-1092
OBJECTIVE To evaluate the long-term cost-effectiveness of canagliflozin or semaglutide in patients with type 2 diabetes mellitus(T2DM)poorly controlled with metformin. METHODS Based on the perspective of China’s health system, a Markov model was used to calculate the long-term costs and utilities of canagliflozin or semaglutide combined with metformin for T2DM patients in China for 30 years based on the data from SUSTAIN 8 study. The incremental cost-effectiveness ratio(ICER) and incremental net monetary benefit (INMB) were calculated using one time the 2024 per capita gross domestic product(GDP) as the willingness-to-pay(WTP) threshold. One-way sensitivity analysis, probability sensitivity analysis and scenario analysis were conducted to confirm the stability of the conclusions. RESULTS Compared with canagliflozin + metformin, ICER of semaglutide combined with metformin was 260 485.67 yuan/quality-adjusted life year (QALY),which was higher than the WTP threshold set in this study (95 749 yuan/QALY),and the corresponding INMB was -61 576.24 yuan,indicating that the canagliflozin + metformin regimen was more cost-effective. The cost of diabetes without complications treatment in the semaglutide + metformin group had the greatest influence on INMB,but changes in parameters within the selected range did not drive decision reversal. With the increasing of WTP threshold,the economic acceptability of semaglutide + metformin regimen increased. Under the current WTP threshold,the annual cost of semaglutide should be reduced by 42.95% to make the semaglutide + metformin regimen more cost- effective. CONCLUSIONS From the perspective of China’s health system, canagliflozin + metformin is more cost-effective than semaglutide + metformin for T2DM patients yueru. with poor glycemic control with metformin alone.